Previous issue | Volume 89 | ESPE2018 | Next issue

57th Annual ESPE

Athens, Greece
27 Sep 2018 - 29 Sep 2018

Card image cap
ESPE 2018 57th European Society for Paediatric Endocrinology Annual Meeting 27-29 September 2018 Athens, Greece

Rapid Free Communications

Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology

hrp0089rfc8.1 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2018

Male Fertility Genes Located in Y-Chromosomal Regions Display Differential mRNA Profiles in Response to GnRH Treatment of Cryptorchidism-Dependent Infertility

Hadziselimovic Faruk , Gegenschatz-Schmid Katharina , Verkauskas Gilvidas , Stadler Michael

Background: Undescended testes in patients with defective mini-puberty contain germ cells that fail to differentiate normally into Ad spermatogonia and ultimately leads to infertility. Six months treatment with the gonadotropin-releasing hormone GnRH increases luteinizing hormone and testosterone secretion and rescues fertility in the majority of pathological cryptorchid testes. Several Y chromosomal genes in the male-specific Y region (MSY) are essential for spermatogenesis, ...

hrp0089rfc8.2 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2018

High Mobility Group Box 1 (HMGB1) is Increased in Adolescents with Polycystic Ovarian Syndrome (PCOS) and Decreases after Treatment with Myo-Inositol in Combination with α-Lipoic Acid (MYO+ALA)

Cirillo Francesca , Catellani Cecilia , Tridenti Gabriele , Vezzani Cristina , Lazzeroni Pietro , Sartori Chiara , Fulghesu Anna Maria , Losi Simona , Coradazzi Letizia , Amarri Sergio , Street Maria Elisabeth

PCOS treatment in adolescence should aim at improving ovarian function, based on the pathophysiology of this condition. We previously described in cystic fibrosis and then in the PCOS an increase in HMGB1, secondary to reduced cystic fibrosis transmembrane conductance regulator (CFTR) expression in the ovary, associated with insulin resistance and inflammation that both characterize PCOS. Inositols and ALA derivatives are considered a good therapeutic option for their possible...

hrp0089rfc8.3 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2018

Pharmacological Treatment of Adolescent Polycystic Ovary Syndrome (PCOS) According to the 2018 International Evidence-Based Guideline for the Assessment and Management of PCOS

Pena Alexia , Witchel Selma , Hoeger Kathy , Oberfield Sharon , Vogiatzi Maria , Misso Marie , Teede Helena

The treatment of Polycystic Ovary Syndrome (PCOS) during adolescence is controversial. The aim of the international evidence-based guideline was to promote accurate diagnosis, optimal consistent care, prevention of complications and to improve patient experience and health outcomes. Extensive international health professional and patient engagement informed the priorities and core outcomes for the guideline. Internationally nominated panels including women with PCOS and a mult...

hrp0089rfc8.4 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2018

Establishing Age, Sex, and Method Related Reference Ranges for Anogenital Distance - a Marker of In Utero Androgen Action

Ljubicic Marie Lindhardt , Thankamony Ajay , Acerini Carlo , Jensen Tina Kold , Main Katharina M , Petersen Jorgen Holm , Busch Alexander S , Upners Emmie , Hagen Casper P , Swan Shanna H , Juul Anders

Background: Anogenital distance (AGD) is an indicator of androgen action in utero. Reduced AGD has been found in males with hypospadias, cryptorchidism, low semen quality and infertility. Its usefulness as a clinical marker in patients with Disorders of Sex Development (DSD) is currently being investigated. However, detailed age, sex and method related reference ranges do not exist. Whether individual (body-size-adjusted) AGD is stable postnatally also remains to be e...

hrp0089rfc8.5 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2018

Latest Progress in Tissue Engineered Urethral Regeneration: From Rabbit to Dog, a Step from Human Clinical Trial for Surgical Treatment of VSD (Variation of Sex Development)

Pinnagoda Kalitha , Vythilingam Ganesh , Vardar Elif , Ballet Eva-Maria , Tambidorai CR , Frey Peter , Larsson Hans-Mattias

Introduction: Treatment of patients with VSD (Variation of Sex Development), in particular severe hypospadias, is associated with high rate of post-operative complications using current surgical procedures. This leads to a high rate of re-operation in an already emotionally complicated situation. We improved the tissue engineered acellular tubular collagen scaffolds that showed promising results in the rabbit model to implant it to a dog model. This FDA approved new version ac...

hrp0089rfc8.6 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2018

Metabolic Profile of Young Adult Transgender Persons Who Started Gender Affirming Treatment in their Adolescence

Klaver Maartje , de Mutsert Renee , Wiepjes Chantal , den Heijer Martin , Rotteveel Joost , Klink Daniel

Purpose: Transgender adolescents are treated with gonadotropin-releasing hormone analogues (GnRHa), followed by the addition of gender-affirming hormones. Since during puberty the body reaches maturation, concerns have been risen that the treatment may have negative outcome later in life. The aim of this study is to determine whether treatment with GnRHa and subsequent addition of hormones results in a more atherogenic profile than peers at the age of 22.<p class="abstext"...